Benefits of early aggressive immunomodulatory therapy (tocilizumab and methylprednisolone) in COVID-19: Single center cohort study of 685 patients BM Luis, MB Miguel, DL Pedro, IP David, A Itziar, GH Ana, IJ Enrique, ... Journal of translational autoimmunity 4, 100086, 2021 | 13 | 2021 |